Generation of iPS cells from normal and malignant hematopoietic cells

International Journal of Hematology

Volumn 98, Issue 2, 2013, Pages 145-152

  Kumano, Keiki ^a,b   Arai, Shunya ^a,b   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Hematological malignancy; Hematopoietic cells; Induced pluripotent cells (iPS cells); Reprogramming

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD34 ANTIGEN; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL FACTOR; TRANSCRIPTION FACTOR SOX2;

B LYMPHOCYTE; BETA THALASSEMIA; BLASTOCYST; BONE MARROW CELL; CELL DIFFERENTIATION; CPG ISLAND; FANCONI ANEMIA; FEEDER CELL; GENE REARRANGEMENT; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOGLOBULIN GENE; LIGHT CHAIN; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROMOTER REGION; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; REVIEW; SICKLE CELL ANEMIA; SOMATIC HYPERMUTATION; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

AMINO ACID SUBSTITUTION; ANIMALS; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION, MISSENSE; NEOPLASTIC STEM CELLS;

EID: 84882281368     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1385-x     Document Type: Review

References (44)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
2. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72.
3. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
4. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008;105:2883-8.
5. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141-6.
6. Togarrati PP, Suknuntha K. Generation of mature hematopoietic cells from human pluripotent stem cells. Int J Hematol. 2012;95:617-23.
7. Watarai H, Yamada D, Fujii S, et al. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol. 2012;95:624-31.
8. Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 2009;460:49-52.
9. Belmonte JC, Ellis J, Hochedlinger K, et al. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet. 2009;10:878-83.
10. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008;133:250-64.
11. Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood. 2009;113:5476-9.
12. Okabe M, Otsu M, Ahn DH, et al. Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood. 2009;114:1764-7.
13. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell. 2009;5:353-7.
14. Eminli S, Foudi A, Stadtfeld M, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009;41:968-76.
15. Takenaka C, Nishishita N, Takada N, et al. Effective generation of iPS cells from CD34(+) cord blood cells by inhibition of p53. Exp Hematol. 2009;38:154-62.
16. Seki Y, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11-4.
17. Loh YH, Hartung O, Li H, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7:15-9.
18. Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20-4.
19. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26:739-40.
20. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920-3.
21. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53-9.
22. Ye L, Chang JC, Lin C, et al. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci USA. 2009;106:9826-30.
23. Wang Y, Zheng C-G, Jiang Y, et al. Genetic correction of [beta]-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res. 2012;22:637-48.
24. Papapetrou EP, Lee G, Malani N, et al. Genomic safe harbors permit high [beta]-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol. 2011;29:73-8.
25. Ye Z, Zhan H, Mali P, et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009;114:5473-80.
26. Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117:e109-19.
27. Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010;115:4039-42.
28. Kumano K, Arai S, Hosoi M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood. 2012;119:6234-42.
29. Lin S-L, Chang DC, Lin C-H, et al. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res. 2011;39:1054-65.
30. Han J, Sachdev PS, Sidhu KS. A combined epigenetic and non-genetic approach for reprogramming human somatic cells. PLoS ONE. 2010;5:e12297.
31. Plews JR, Li J, Jones M, et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS ONE. 2010;5:e14397.
32. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269-75.
33. Li H, Collado M, Villasante A, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460:1136-9.
34. Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460:1145-8.
35. Maclean GA, Menne TF, Guo G, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA. 2012;109:17567-72.
36. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877-86.
37. Chou ST, Byrska-Bishop M, Tober JM, et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA. 2012;109:17573-8.
38. Mou X, Wu Y, Cao H, et al. Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res Ther. 2012;3:14.
39. Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011;117:5561-72.
40. Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011;118:4599-608.
41. Sebastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells. 2011;29:1717-26.
42. Li M, Suzuki K, Qu J, et al. Efficient correction of hemoglobinopathy- causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res. 2011;21:1740-4.
43. Müller LU, Milsom MD, Harris CE, et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012;119:5449-57.
44. Jiang Y, Cowley SA, Siler U, et al. Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells. 2012;30:599-611.